Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab + Daratumumab vs DPd or DVd in Relapsed/Refractory Multiple Myeloma
NCT05083169Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of teclistamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Oct 2021; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05083169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083169.